Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
220 hedge funds and large institutions have $4.52B invested in Medicines Co in 2017 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 87 increasing their positions, 62 reducing their positions, and 22 closing their positions.
136% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 22
75% more funds holding in top 10
Funds holding in top 10: 8 → 14 (+6)
62% more capital invested
Capital invested by funds: $2.79B → $4.52B (+$1.73B)
40% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 62
31% more call options, than puts
Call options by funds: $101M | Put options by funds: $77.5M
13% more funds holding
Funds holding: 195 → 220 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$442M |
| 2 |
AH
Aviva Holdings
New Providence,
Bahamas
|
+$175M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$94.6M |
| 4 |
Goldman Sachs
New York
|
+$62.2M |
| 5 |
TBC
Three Bays Capital
Boston,
Massachusetts
|
+$62.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$39.5M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$36.3M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$26.2M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$21.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$20.1M |
MDCO Hedge Fund Activity: Q1 2017 in Review
220 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q1 2017, worth a combined $4.52B — up 62% from $2.79B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new MDCO positions and 22 closed out — a net gain of 30 holders — while 87 added to existing stakes and 62 trimmed.
The largest buyer was BlackRock, adding an estimated $442M. The largest seller was PFM Health Sciences, cutting an estimated $39.5M.
- 220 institutional investors held Medicines Co (MDCO) as of Q1 2017, up from 195 in Q4 2016.
- Funds reported $4.52B of Medicines Co stock for Q1 2017, up 62% quarter-over-quarter.
- 52 funds opened new Medicines Co positions in Q1 2017 and 22 closed out, a net change of +30 holders.
- The largest Medicines Co buyer in Q1 2017 was BlackRock, an estimated $442M added.
- The largest Medicines Co seller in Q1 2017 was PFM Health Sciences, an estimated $39.5M sold.
Based on aggregated 13F filings for Q1 2017.